Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-D-glucan guided antifungal stewardship in severe abdominal sepsis
2016-002335-14Phase 3Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amphotericin b in sepsis, septic shock, invasive candidiasis and 1 more, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Safety of pre-emptive liposomal amphotericin B therapy and Cost-effectiveness of β-D-glucan guided antifungal management. Started Nov 2020; status: completed.
02
Drugs
amphotericin b
03
Conditions
sepsisseptic shockinvasive candidiasisIntra-abdominal candidiasis (IAC)
Beyond the preview
Go deeper on 2016-002335-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002335-14.